The first step in the therapy of lung and hematological cancers is adequate diagnosis. Analysis of circulating tumor DNA by massively parallel sequencing is a non-invasive approach for early detection without a tissue biopsy. This approach is also promising for the development of a test for selection of cancer patients who could benefit from immunotherapy and precision medicine.